KRT-232 is under development by Kartos Therapeutics for treatment of myelofibrosis, polycythemia vera, acute myeloid leukemia (AML) and Merkel cell carcinoma (see NCT03662126, NCT03669965, NCT03787602). Study 20120106 was a 2-part Phase 1 dose-exploration/dose-expansion study of KRT-232 in ...
KRT-232 is under development by Kartos Therapeutics for treatment of myelofibrosis, polycythemia vera, acute myeloid leukemia (AML) and Merkel cell carcinoma (see NCT03662126, NCT03669965, NCT03787602).\nThe KRT-232 no effect-level for in vitro inhibition of hERG function (10 渭M) was ...
Together, these studies provide biological and clinical support for evaluating navtemadlin in patients with R/R AML secondary to MPN.Methods:The open-label, multicenter Phase 1b/2 KRT-232-104 study (NCT04113616) is evaluatingTP53WTpatients with R/R AML secondary to MPN (myelofibrosis, ...
An Open-Label, Phase 2 Study of KRT-232, a First-in-Class, Oral Small Molecule Inhibitor of MDM2, for the Treatment of Patients with Myelofibrosis (MF) Who Have Previously Received Treatment with a JAK InhibitorBackground: Myelofibrosis (MF) is a myeloproliferative neoplasm (MPN) characterized...
An Open-Label, Global, Multicenter, Phase 1b/2 Study of KRT-232, a First-in-Class, Oral Small-Molecule Inhibitor of Murine Double Minute 2 (MDM2), Combined with Ruxolitinib in Patients Who Have Myelofibrosis and a Suboptimal Response to Ruxolitinib...